Tags : Chinese Patients

BeiGene Reports Updated Results of Tislelizumab in P-II Study in

Shots: The P-II (NCT03209973) study result involves assessing of tislelizumab (200mg, IV, q3w) as a monothx. in 70 patients with R/R to autologous stem cell transplantation (ASCT) or 2L+ r/r cHL The P-II study results: high anti-tumor activity in patients; ORR (87.1%); CR (62.9%); PR (24.3%); @12mos. PFS (73.8%); well tolerated; presented at 24thCongress of […]Read More